Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given a $35.00 target price by investment analysts at Maxim Group in a note issued to investors on Thursday, May 11th. The brokerage currently has a “hold” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 13.20% from the stock’s previous close.
Several other analysts have also recently commented on TEVA. Oppenheimer Holdings, Inc. set a $43.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, April 6th. Royal Bank of Canada reissued a “sector perform” rating and set a $42.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, February 21st. Deutsche Bank AG reissued a “buy” rating and set a $48.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, January 31st. J P Morgan Chase & Co cut Teva Pharmaceutical Industries Limited from an “overweight” rating to a “neutral” rating in a research report on Friday, January 20th. Finally, Mizuho cut Teva Pharmaceutical Industries Limited from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $40.00 to $27.00 in a research report on Friday, February 10th. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.56.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 30.92 on Thursday. The stock has a market capitalization of $31.41 billion, a P/E ratio of 396.41 and a beta of 0.49. Teva Pharmaceutical Industries Limited has a 52-week low of $27.59 and a 52-week high of $56.44. The firm’s 50-day moving average price is $30.19 and its 200-day moving average price is $33.22. Teva Pharmaceutical Industries Limited also saw some unusual options trading on Thursday. Stock investors purchased 2,342 call options on the stock. This represents an increase of 232% compared to the typical daily volume of 705 call options.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.06. The business had revenue of $5.63 billion for the quarter, compared to analysts’ expectations of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The company’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.20 EPS. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.79 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, June 1st. This represents a $1.36 annualized dividend and a yield of 4.40%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently 5,802.90%.
TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Given a $35.00 Price Target at Maxim Group” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.com-unik.info/2017/06/17/maxim-group-analysts-give-teva-pharmaceutical-industries-ltd-teva-a-35-00-price-target-updated-updated-updated.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Cribstone Capital Management LLC boosted its position in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. Elite Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited during the third quarter valued at approximately $166,000. Bronfman E.L. Rothschild L.P. boosted its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares in the last quarter. Crow Point Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited during the third quarter valued at approximately $169,000. Finally, CKW Financial Group acquired a new position in shares of Teva Pharmaceutical Industries Limited during the third quarter valued at approximately $168,000. 56.34% of the stock is currently owned by hedge funds and other institutional investors.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.